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Abstract
OBJECTIVES: The increase in oral anticancer medications with complex regimens creates a need to assure patients
are taking therapeutic dosages as prescribed. This article reviews the assessment and measurement of
adherence to oral antineoplastic agents.

DATA SOURCE: Research and journal articles from CINAHL and Pub Med.

CONCLUSION: Assessing and measuring adherence to oral antineoplastic should include three
dimensions: the percentage of medications taken, the duration, and the timing of taking the medication.

IMPLICATIONS FOR PRACTICE: Clinicians need to conduct ongoing assessment and measurement
of adherence to oral antineoplastic agents. This includes eliciting patient report of adherence, pill counts,
drug diaries, and pharmacy or medical record audits.
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Introduction
Despite efforts of providers, pharmaceutical manufacturers, and healthcare providers to
encourage adherence, irregular and incomplete oral therapeutic drug dosing is common and may be
particularly troublesome among cancer patients prescribed oral antineoplastic agents.1,2 Consequently,
clinicians need to conduct ongoing assessment and measurement to assure that a prescribed oral
antineoplastic agent is taken appropriately.3 In this paper, the assessment and measurement of adherence
to oral antineoplastic agents for cancer treatment are discussed.
Therapeutic Oral Antineoplastic Agent Dosing
A large body of literature has reported that adherence to standard chemotherapy doses and
schedules can have a positive effect on treatment outcomes. This literature and the theories that
characterized the relation of the doses of chemotherapy to efficacy are summarized in the AMGEN®
Relative Dose Intensity newsletter endorsed by the Oncology Nursing Society.4 To summarize, this
includes higher doses reduces the likelihood of survival of chemotherapy-resistant clones; that decreasing
the interval between chemotherapy cycles can result in greater treatment efficacy; that a percentage of
cells may be killed with each does; and that tumor cells grow between cycles of chemotherapy, yet cell
growth is the greatest when tumor cell burden is the smallest. These theories can then be used to explain
the impact of non-adherence (dose delays or reductions) for oral antineoplastic agents. The importance of
maintaining a therapeutic drug level in the curative cancer treatment setting is discussed at the beginning
of this article to provide clinicians with an awareness of the need to improve the delivery of oral
antineoplastic agents by minimizing dose reductions and dose delays.
The Complexity of Oral Antineoplastic Agents
Some oral antineoplastic agents have simple regimens, while others are extremely complex. Drug
manufacturers attempt to simplify the regimen by developing dosing schedules that are simple. However,
the nature of oral antineoplastic agents does not lend itself towards simple regimens. An example of a
simple regimen is continuous daily doses as long as the medication is prescribed. An example of a
complex regimen is twice daily doses 30 minutes after a meal and 12 hours apart, administered in 21-day
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treatment cycle of 2 weeks of the treatment followed by 1 week rest period. Other examples are provided
in Table 1. Further complicating the complexity is when 2 antineoplastic agents are prescribed
simultaneously and administered on an alternating schedule. Additionally, medications the patient may be
taking for other conditions can interfere with the oral agent regimen.
Obtaining the oral agent is a complicated procedure for the patient, family member, or caregiver,
and can lead to problems with adherence. First, the prescription for the oral antineoplastic agent must be
obtained from the oncologist. Second, the prescription must be filled, and some scripts are sent by the
oncologist to a specialty pharmacy while some patients fill prescriptions themselves. To further
complicate the filling of the prescription, some oncologists’ orders are partial scripts and in some
instances, prescriptions are partially filled by the pharmacy. Partial prescriptions are written or filled
when modifications to the regimen are expected, as there is a desire to not waste expensive medications
that may not be used. Third, is the delivery of the pills. Some pills are picked up by the patient at the
pharmacy, some are delivered directly to the home while others are mailed, which can create problems
with early or late arrival of the pills. Another important component of filling the prescription is when
patients actually receive the prescription as compared to when they should initiate their dosing. The
timing of the receipt of the pills can be a problem, as some prescriptions are filled a week or two prior to
initiation of the dosing, which can create confusion for the patient, family or caregiver, with regard to
when the patient should start the medication; upon receipt of the pills from the pharmacy or on a specified
date in the regimen cycle. Finally, another important component is how the pills are packaged. This can
include a bulk quantity in a pill bottle or pre-packaged blister pack containers, which are labeled for daily
use. A seldom examined step in this procedure is, once a patient has the pills, how clearly do they
understand the dosing regimen procedures (duration, timing, with or without foods or liquids). Further, to
fully appreciate the complexity of patient adherence to oral therapeutic agents, changes made by
oncologists during the course of treatment can be made during the beginning or middle of a filled
prescription. If and how those changes affect pills to be taken from the already prescribed and received
pill order are not taken into account, the patient may become confused and not take the correct dosage.
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Unfortunately, little information is available on filling of prescriptions for oral therapeutic agents, an
important component of care. These potential threats to adherence have not been systematically addressed
and need to be included in future research on adherence to oral antineoplastic agents.
The Importance of Defining Adherence Prior to Assessment and Measurement
Precise definition of adherence prior to assessment and measurement is imperative.5 Lack of a
clear-cut description of the meaning of adherence when assessing and measuring the concept may create
confusion and miscommunication in clinical practice. Chapter 2 identifies the International Society for
Pharmacoeconomics and Outcome Research (ISPOR) definition of adherence to medications for this
article. ISPOR defines adherence along two dimensions: first as “the degree or extent of conformity to the
recommendations about day-to-day treatment by the provider with respect to the timing, dosage, and
frequency”; and, second as the persistence which they define as “the duration of time from the initiation
of the medication to discontinuation of therapy”.6 Some measures of adherence are simple, while others
are detailed and complex. A simple, commonly used measurement of adherence is a percent of the
prescribed dose taken (where the numerator is what was taken ordered and the denominator is what was
prescribed).7 An example of a more complex operational definition of adherence includes the prescribed
number of doses taken as determined by pill count as confirmed by the a Medication Event Monitoring
System (MEMS [electronic pill boxes that alarm and measure cap openings]) within 2-hours of prescribed
time of the dosing interval and with the correct number of doses on each time of day and day of
treatment.8
The main point in regard to defining adherence is that clinicians need to clearly understand which
dimensions of adherence they are assessing and measuring when caring for patients on oral antineoplastic
agents. In most instances, this should include three components. First, the percentage of medications
taken must be defined (to include number of doses and doses by day of treatment). Second, the duration
(i.e., number of days, weeks, months, or years) of taking the medication (persistence) is needed. Finally,
with some types of medications, the timing of taking the medication is of importance (a defined dosing
interval, i.e. at a specific time of day so that under and overdosing can be evaluated), as well as taking the
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oral antineoplastic agent lying down or with or without food. Next, the assessment and measurement of
oral antineoplastic agents is reviewed.
Methods of Assessment and Measurements of Adherence Commonly Used and their Limitations
Despite the importance of adherence to clinical care and therapeutic outcomes, little rigorous research
has been completed to measure adherence to complex dosing because they require direct observation and
long-term assessment. Because of the time and cost involved in measuring adherence, often only one
method of assessment is used. Furthermore, the degree to which adherence can be legitimately assured
from measures such as self-report are questionable.9 To conduct evaluation of adherence to oral
chemotherapeutic agents a number of difficulties must be overcome. First, to properly assess adhere, the
prescription regimen including dose, timing, and duration must be identified, and any ongoing adjustments or
modification to the dose, timing, and duration. Next, a clear definition of what adherence entails must be
identified (i.e., percentage of adherence based on number of pills and days to be taken [80%, 90%, 100%]) and
the numerator and denominator to calculate this percentage clarified. If timing of the dosage is required, the
window of time that must elapse before a patient is considered to be nonadherent [i.e., 1-hour; or 30-minutes])
must be identified. Strict attention must be paid to underdosing and overdosing, so that missed doses of
medication and additional doses of medication are assessed. Finally, the assessment and measurement of the
patterns of nonadherence must be sensitive enough to capture both the frequent, as well as erratic, occurrences
of nonadherence. However, the majority of adherence measures are indirect and include some form of
self-report and cannot truly capture if the medication was actually taken. Furthermore, even if all of these
complexities are assessed and measured in a research setting, translation into a clinical setting may be time
consuming and therefore impractical.
Previous studies have shown that adherence measures have limitations, prompting questions
about how best to measure drug-taking behavior.10,11 Although drug levels are a direct measure of drug
exposure, they provide only a snapshot of behavior and are affected by factors other than adherence.
While, indirect measures cannot truly capture if the medication was actually taken. Each of these
available measures and their limitations will be reviewed.
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Direct Methods of Measuring Adherence
Physiological biomarkers to measure adherence. Serum or urine drug metabolite levels are
more objective measures of adherence, but do not describe the timing of doses and can still be
manipulated by patients (medication dosing can be resumed or extra doses can be taken before an office
visit to avoid appearing nonadherent).12 Additionally, because of pharmacokinetic variability in drug
absorption, distribution, metabolism, and excretion, ranges that are consistent with adherence may be
wide.12 Furthermore, accurate measurement of serum or urine drug metabolites is only available for
certain drugs (e.g., prednisone and 6-mercaptopurine [6-mp]).12 However, in some diseases, intermediate
markers of drug use may be useful. For example, plasma viral load in patient with the human
immunodeficiency virus (HIV) can act as a surrogate for adherence to antiviral therapy.13 However, most
of the oral drugs used to treat cancer do not at this time have intermediate markers of adherence that can
be easily measured in a clinical setting. This is something that might be developed in the future to ensure
therapeutic dosing and effectiveness.
Indirect Methods of Measuring Adherence
Pill counts. Pill count is also commonly used to measure medication adherence in research, but it
is too time-consuming and computationally complex for most clinical purposes. Several studies
emphasized the shortcomings of pill counts in overestimating adherence, often due to “medication
dumping”.14 Pill counts, requiring patients to return unused pills at each visit so that the number of missed
doses can be calculated, have also been shown to overestimate the number of pills actually taken.15,16
Patients may throw away missed doses to avoid being viewed as nonadherent. Nonetheless, pill counts are
often used as an adjunct to self-report. However, most clinicians do not have the time to perform the pill
count, making this an impractical method of assessing adherence day-to-day. Technology has been
developed to facilitate pill count measurement. This includes blister packs or a MEMS pill boxes that
contain a microchip and reports each time the container is opened. The iPill application, where a patient
can touch the screen and record when (date and time) the pill is taken, might make pill counts somewhat
easier in the future.
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Pharmacy and administrative records. Although pharmacy and administrative records are a
convenient source of adherence information they are time consuming to evaluate and only report if the
prescription was filled, not if the medication was actually taken.17 Analysis of prescription refills can be
calculated as the proportion of days within a given time period during which a patient has filled
prescriptions (i.e., “days covered”).12 Using pharmacy records may falsely demonstrate adherence, as it is
possible that some patients may miss and/or double up on pills and still refill prescription on time, and
there is no information provided regarding the timing of doses. Furthermore, some prescription refill
studies fail to separate nonadherence from lack of persistence because they simply estimate the proportion
of days a patient had pills available, not distinguishing between those who are taking the medication
incorrectly and those who stop the medication entirely.18 Nevertheless, the strength of studying refill rates
is that it provides an objective measure of adherence available in a large population over a long period of
time. Using pharmacy or insurance records also avoids the Hawthorne effect (i.e., when a patient is being
monitored for taking their medication they are adherent, but when the observation stops the patient is no
longer adherent), as well as patient manipulation for social desirability because subjects would generally
not be aware that their refill rate was reviewed.12 Another issue related to the use of pharmacy records to
measure adherence is that pharmacies deliver or mail oral therapeutic agents to the home prior to when
the medication is to be taken and do not identify on the prescription when the patient is suppose to start
the medication, which may be confusing.
Medical record review and healthcare provider reports. The medical record is also a source of
prescriptions ordered, modifications to the regimen, and adherence.19-27 However, medical records are
known to be incomplete or inaccurate.28 When electronic medical records are fully implemented, this may
become a more reliable source of information. Healthcare provider interviews are also known to be
inaccurate, due to problems with recall of specific patient care events or the provider not being aware of
patient adherence as the patient wants to please the provider and does not report nonadherence.28 Patients
also often report appropriate adherence to medications so as not to appear socially undesirable to their
physician. Regardless of the format of the record review or provider reports, what is still not known is if
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the patient actually took the pill. In most instances, record review and provider reports measures were
used in conjunction with other assessment techniques to supplement data.
Self- or caregiver report of adherence. Patient self-report has been used extensively to assess
medication-taking. This method tends to overestimate adherence as the questions asked are not specific
enough to get at all dimensions of adherence (i.e., time taken, took with grapefruit juice, laid down for 30
minutes, etc.).29,30 Self-report, in which patients are asked to recall how accurately they followed their
prescribed regimen, have been repeatedly shown to suffer response bias, with patients usually overreporting rates of adherence because of desire to please providers.31 Patient-completed diaries may
provide flawed information regarding adherence for the same reason, although they may be less
susceptible to recall bias because the patient is asked to record each dose as it is taken.12 Furthermore,
cognitive impairment due to aging, disease process, or side effects of the medications can influence
memory and ability to remember if the medication was taken properly. Finally, when caregiver reports of
medication adherence are used, overestimation often occurs.28
Relative dose intensity. A novel method of assessing adherence by examining the therapeutic
level of the dose of the oral antineoplastic agent is identified in the AMGEN® newsletter4 discussed
earlier. This includes two methods of analysis. Delivered dose intensity (mg/m2/unit time) is total dose
delivered over total time to complete the chemotherapy. Relative dose intensity is the ratio (percentage) of
delivered dose intensity to standard (referenced) dose intensity, often expressed as a percentage.4 These
calculations are depicted in Figure 1.
Electronic medication monitoring system. A novel approach for the measurement of adherence
is the MEMS®.32,33 The MEMS® consists of an “intelligent” cap that electronically records every time
the cap of the pill bottle is removed. MEMS data provides a computerized record of each date and time
the bottle is opened. The MEMS® provides an objective measure of pill bottle opening, but it is not
effective when pill storage devices are used or for liquid medications, and only records the bottle opening
and not the ingestion of the medication. Even with the more objective measures, data may still be
influenced by the Hawthorne effect and patient desire to appear optimally adherent. Furthermore, the

10

MEMS® technique is quite expensive and therefore is used primarily in clinical research and is not
feasible in many other settings. The MEMS® is also not able to evaluate if pills were taken at the
appropriate time of day as prescribed, only that the cap was opened.
A new electronic medication monitoring system in development and testing for both the research
and clinical setting is the Maya® from MedMinder.34 The tool is plugged into an electrical outlet and
uses an internal wireless modem to communicate with a central server, so the patient has no need for a
computer, wireless router or any form of internet access. The electronic pillbox prompts the patient to
take the pill(s) with a visual or auditory alert. If a pill cup is not removed at the scheduled day and time, a
compartment in the pillbox starts to flash; and if the pill cup is not removed after a period of time, other
alerts, such as beeps, phone calls, emails or text messages can be initiated. The electronic message can be
sent to a family member or caregiver to assist with medication adherence. A summary statement of
pillbox use can be sent to the clinician to evaluate adherence. The pillbox uses a web interface so a patient
can program the cups in the pillbox or call, fax, or mail a company provider to program the regimen. The
pillbox can also be refilled in a blister pack, for ease in managing a complex regimen, such as oral
therapeutic agents. The pillbox is currently being tested in two control trials (NCT01105104 and
NCT01188135) promoting medication adherence for patients with heart and kidney disease.
iPhone® and iPill®. There is a new application for the iPhone® called iPill® for tracking
medication management.35 iPill® acts as a virtual pillbox, allowing a person to easily see what
medications have been taken and what medications are left to be taken. A picture of what a pill looks like
can be inserted into the medication regimen schedule and the patient taps the picture of the pill when it is
taken to record ingestion. iPill can set up a schedule with intervals and alarms as a reminder when to
ingest the pill, and can provide a complete record of all medications taken, time taken, and missed doses.
Studies need to be conducted examining the efficacy of cell phone pill reminder alarms and adherence, as
none were found. Although the iPill® application is not expensive, a prohibiting factor may be the cost of
the iPhone and its associated monthly fee.
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Tools used in Research to Measure Adherence
There are a few research tools to measure medication-taking behavior of adherence in the
research setting. These tools do not measure specifics of taking pills, but instead focus on attitudes or
behaviors associated with medication adherence. The two commonly used tools are the Morisky36 and the
Brief Medication Questionnaire (BMQ).37 The Morisky medication adherence scale, developed in 1986,
is composed of 4 yes/no questions about past medication use patterns and is thus quick and simple to use
during drug history interviews.36 The BMQ is a self-report tool for screening adherence and barriers to
adherence that includes 5 items asking patients how they took each medication in the past week, 2 items
that ask about drug effects and bothersome features, and 2 items that ask about potential difficulties
remembering.37 Research studies on adherence, and particularly the studies examined for this review,
used modified versions of the questions in one of these two tools to interview patients about
adherence.24,25,38 One study used a single question from the Hot Flashes and Nights Sweats Questionnaire
for adherence, “In the past week have you taken your Tamoxifen every day?”39 In addition to there being
few research tools to measure medication adherence, the ones that do exist do not appear to obtain the
range of information (dosage, timing, duration) necessary to examine adherence to oral antineoplastic
agents.
Summary. After analyzing 50 years of adherence research, DiMatteo28 found that research
studies employing certain objective measures of adherence (such as pill counts and physical measures)
registered somewhat better average adherence than studies using subjective measures such as self-report.
Evaluation of adherence to oral antineoplastic agents requires the use of 2 or more methods including the
dosage, timing, and duration. The only way to build a library of reliable and valid methods of
measurement of oral therapeutic agent adherence for research is to use the multi-method approach.40
However, translating these methods to the clinical setting is a challenge. A review of the literature on
adherence to oral antineoplastic agents provides some direction for clinicians.
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An Integrative Review of Literature on Measurement of Adherence to Antineoplastic
There is a wide range, diversity, and variable pattern of medications patients use at home, making
adherence particularly challenging. Pharmionics is an emerging field concerned with quantitative
assessment of what patients do with prescription drugs.41 Recent research in the field of Pharmionics has
revealed three major findings.41,42 The first is the recognition of the need to analyze adherence and
persistence separately. Second is an understanding that adherence influences persistence, in part through
the impact of patient perceptions of therapeutic outcome, and in part through the impact of beneficial
and/or adverse effects. The third is the discovery that intervals between dosages are often ‘the’ most
important factor in determining the clinical and economic consequences of nonadherence from a
prescribed dosing regimen. This is particularly true in the case of oral antineoplastic agents. The dosing
and timing regimens are often complex, with cycles of days-on and days-off often referred to as absences,
rest periods , or drug free days and most chronic disease do not have that type of disrupted routine.
Furthermore, the side effects, potential adverse events due to toxicity, and polypharmacy can disrupt
administration making adherence difficult. Moreover, many of these medications must be taken over
extended periods of time, often for years, making persistence a challenge.
Research literature on assessment and measurement of oral antineoplastic agents. Relatively
few published studies have focused on adherence to oral antineoplastic for cancer treatment. In part this
occurs because the vast majority has been delivered intravenously.43 A search strategy to identify studies
that examined adherence to oral antineoplastic among oncology patients was conducted. A CINAHL and
Pub Med search for English-language articles published between 1975 and 2010 was performed, linking
the subject search headings “compliance”, “adherence”, with “chemotherapy”, “oral therapy”, and
“antineoplastic agents.” Reviews were restricted to those with adherence as a primary outcome. Manual
searching of the reference lists within relevant articles identified additional studies. This review identified
3 systematic reviews, 30 adult studies and 13 pediatric studies (Table 2.). This review included
assessment and measurement of adherence to both “hormonal” and “non-hormonal” agents. This was
done to incorporate lessons learned from all available previous studies on oral agents in oncology
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patients. Three systematic reviews12,43,44 examining oral antineoplastic in oncology patients. Overall, these
reviews verified that adherence to oral antineoplastic agents is variable, not easily predicted, with
adherence rates of 20% to 100% reported. Furthermore, no “gold” standard definition, and in some
instances no definition, of adherence made comparison of results between studies difficult.
The adult adherence literature includes 12 hormonal studies and 18 non-hormonal studies and the 13
pediatric studies included more non-hormonal drugs (Table 2.). A majority of the hormonal studies
conducted examined Tamoxifen adherence using pharmacy records.21,22,45-49 Although, the lessons learned
from these studies support the importance of including prescription refill information and methods of
calculating the number of days covered by filled prescriptions in future studies of one of the many
multivariate measures. Two Tamoxifen studies also conducted phone interviews regarding adherence,
asking patients if they continued taking their medication,21,39 while another taped interviews50 questioning
reasons why pills were not taken. The two most common reasons for nonadherence were side effects from
the medication and that there was nothing to be gained by taking the medication. These studies provided
important lessons for future studies of oral agent adherence, regarding use of self-report as a measure and
eliciting patient input to better understand reasons for nonadherence.
Drug trials testing effectiveness of the oral route use multivariate measures of adherence. This
includes MEMS, pill counts, self-report or diaries, medical record review, and pharmacy record
review.7,51-54 Several ‘tightly’ controlled drug trials noted over adherence or overdosing when medications
were not stopped or resumed at the proper time. Overall, minimal attention has been paid to the
potential hazards related to overdosing. This is also an important lesson learned when assessing and
measuring adherence, to include questioning regarding the timing of taking the medication.
Self-report (to include drug diaries) was by far the most commonly used measure of adherence, with
24 studies using this method.7,20,21,23-25,38,39,50,51,55-59 Although the MEMS is touted as a “gold standard”
measurement in medication compliance, only 6 of the adult studies8,48,52,53,60 and one pediatric study61 used
this method of measurement. MEMS is not considered to be a practical tool in the clinical setting due to
its excessive cost. Pill counts7,56 and medical record clinical note audits occurred,19-23,25,62 yet were not
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very common, probably due to the labor intensive nature of conducting these measures. Direct serum or
urine55,57 measures were rare in adults, yet very common in pediatric oncology.26,63-72 However, these
measures can only occur in the clinical setting when feasible and cost effective.
Summary. Collectively, this provides a state of the science on assessment and measurement of
adherence to oral antineoplastics. To date, assessment and measurement of adherence has included selfreport, use of MEMS, pill counts, record review, and in some instances, biologic measures. Based on
these studies, use of multiple assessment and measures of adherence is recommended, as no measure
alone can confirm adherence. However, minimal information is available on the cost of or time it takes a
clinician to implement these assessment and measurement techniques in a “real” clinical setting. An
understanding of the factors contributing to adherence provides some direction to clinicians when caring
for patients on oral antineoplastic agents.
Patient Characteristics Contributing to Adherence and Implications for Practice
There are many factors that can influence adherence. These factors are important to take into
consideration when assessment and measuring if a pill was taken. Correlations between adherence and
sociodemographic factors, while somewhat statistically significant, are generally quite modest in
magnitude (r<0.15 in all cases),28 yet must be examined when conducting adherence research.
Psychological factors of depression,73,74 anxiety,75,76 and self-efficacy seem to contribute to adherence.
20,21,24,25,50,58

Although type of disease is known to influence adherence in certain circumstances,77-80 there

is a paucity of information on cancer stage and its effects on adherence, and these data need to be
included in future adherence research. In cancer patients, the gravity of the disease may produce
adherence in some patients. Conversely, a sense of fatalism may prevail in other patients leading to nonadherence. Studies of cancer and non-cancer diseases indicate that patients decrease adherence as
symptoms and side effects occur.73,81-85 Few studies to date have linked symptom severity with nonadherence86 and further study is needed. Adherence is inversely related to medication regimen
complexity87 Incorporating a medication calendar into each study is imperative. Cognitive impairment
due to the disease or its associated treatment, or age 88 is also known to influence adherence and should be
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measured. Comorbidities and associated polypharmacy can lead to adverse clinical outcomes, and it may
be difficult to assess and measure the difference between outcomes related to polypharmacy and
symptoms or adverse events related to the oral agent.89-91 Finally, adherence correlates with patients’
beliefs in the severity of the disease to be prevented or treated,92-94 and there are some tools (i.e., BMQ)
that examine expectations about medications that can be incorporated into daily practice. Although many
of these factors may have modest influence on adherence, it is imperative to assess each element to better
understand where clinicians could influence adherence.
Drug-to-drug Interactions, Symptoms, Adverse Events and Adherence to Oral Antineoplastic
Agents
Sorting out the difference between drug-to-drug interactions (a change in the way a drug acts in
the body when taken with certain other drugs), symptoms (an indication a person has a condition or
disease) caused by side effects of the disease, and adverse events (an unexpected medical problem that
happens during treatment with a drug) is truly a challenge. Assessing and measuring the difference
between these three elements is a daunting task. For example, complexity of disaggregating the affects
from oral agents alone, compared with their interactions with other drugs and how, together, they may
produce adverse events may lead patients to discontinue or alter dosages of all medications. Sorting out
the difference between these three problems has implications for assessment and measurement of
adherence. Evaluation of symptoms and monitoring adverse events needs to be based on the known
effects of the specific oral therapeutic taken by a patient, and is needed in both the research and clinical
setting. Furthermore, to effectively evaluate drug-to-drug interactions, a review of medications should
include ‘all’ prescription and over-the-counter medications taken. An example of a summary for known
effects of oral therapeutic agents is shown in Chapter 3. Use of assessment measurement tools that are
sensitive enough to detect changes in a patient’s condition to identify differences in drug-to-drug
interactions, symptoms, or adverse events would be necessary when conducting research.
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Conclusions
Providing efficacy and tolerability are not compromised, oral antineoplastic agents can be
attractive to patients because of the associated benefits in convenience, avoidance of visits to the clinic,
and reduced impact on daily activities.1 Daily or more frequent dosing provides numerous opportunities
to modify the dose and effectively manage side effects, also making oral antineoplastic agents more
attractive. However, adherence to oral antineoplastics is a major obstacle to successful oncology
treatment, while over adherence can lead to potentially life-threatening toxicity. The challenge is to assure
that the oral therapeutic is taken as prescribed. With the increase in the number of oral anticancer agents
available during recent years, a simple and cost efficient mechanism to assess and measure adherence in
the clinical setting needs to be developed.
Implications for Research
Assessment and measurement of adherence to oral antineoplastics in research should include a
multivariate, multimethod approach. Multivariate assessment and measurement of adherence in the
oncology population should also include a range of known risk factors for nonadherence. This includes
socio-demographics, psychological self-efficacy type of disease and stage, medication regimen
complexity, cognitive impairment, comorbidities and associated polypharmacy, and the patient’s belief in
the severity of the disease to be prevented or treated. Multiple tools exist that can measure these factors.
The multimethod approach to assessment and measurement of adherence could include self-report, use of
a medication reminder system (i.e., MEMS or calendars), pill counts, record review, and when possible,
biologic measures. New pill reminder systems like the iPill® application on the iPhone® and the Maya
MedMinder® need to be tested in the research setting to determine if improved adherence rates occur.
Implications for Nursing Practice
Although some interactions may be only 5 minutes, addressing oral therapeutic adherence can
become second nature as clinicians work seamlessly from one patient to the next.95 As shown in detail in
Chapter 5, promoting and assuring adherence begins with educating the patient, family, or caregiver when
the medication is prescribed. Clinicians can introduce medication reminders that may help the patient
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adhere to the oral therapeutic(s), such as pill-boxes, alarms, or calendars. Patient-generated
documentation in a diary or medication log may also help avoid the need to question patients during
office visits, which may lead them to become defensive if they feel blamed for not adhering to the oral
therapeutic.96 Then, at a minimum, clinicians need to assess for risk factors that may influence adherence,
and then ask patients if they are taking their oral therapeutic agents as directed, what they expect or are
experiencing from the oral therapeutic agents, and whether they are having any problems with adherence
to include all dimensions, prescribed timing, dosage, frequency, and persistence.2,97 The line of
questioning should come across as nonthreatening and nonjudgmental, with the goal of understanding the
patient’s issues.95 Consider asking open-ended questions such as these:


What are you taking this oral therapeutic agent for?



What dose are you taking?



What time of day are you taking your pill?



How many days/months have you taken your pill?



What causes you to miss your oral therapeutic agent?



What helps you remember to take your oral therapeutic agent?



What motivates you to stay on this oral therapeutic agent?



What side effects or symptoms can you live with, and which ones would make you consider
stopping your oral therapeutic agent?

Clinicians can play a key role in improving oral antineoplastic agent adherence by conducting
ongoing assessment and measurement. The key is to communicate with the patient, focusing on solutions
to promote oral therapeutic agent adherence, despite the limited time that clinicians have to address the
issue.
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Figure 1. Delivered Dose Intensity and Relative Dose Intensity

Delivered Dose

Total Dose Delivered

Intensity =

Total Time to Complete Therapy

Relative Dose

Delivered Dose Intensity

Intensity % =

Standard Dose Intensity

x100

Standard dose = 100% of prescribed dose
Total delivered dose = percentage of what patient actually took
Standard duration of treatment = number of weeks dose prescribed to be taken
Actual duration of treatment = number of weeks dosage was actually taken by patient
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